

REMARKS

The amendment in the specification is supported in the originally filed specification, e.g., in Example 9 and Figure 15 and as described below. Newly added claims 120-123, drawn to an antibody against ChemerinR and said antibody being a monoclonal antibody, are adequately supported in the specification, e.g., in Example 9 and as described below. No new matter is added.


For example, Example 9 (page 76) teaches the making of ChemerinR antibodies. Figure 15 shows the characterization of antibodies directed against ChemerinR by flow cytometry according to one embodiment of the invention. The specification specifically discloses two monoclonal antibodies against ChemerinR, e.g., 4C7 and 1H2 (e.g., on page 76, lines 18-21, and pages 32-38).

The specification also teaches that the ChemerinR antibodies (e.g., 4C7 and 1H2) are capable of blocking the receptor activation by chemerin, e.g., page 76 and Figure 26. Example 18 of the present specification (on page 85) specifically teaches a detailed Ca^{2+} mobilization assay to measure the effect of a ChemerinR antibody on the activation of ChemerinR. The specification also teaches how to measure the binding of a Chemerin polypeptide to a ChemerinR polypeptide (e.g., page 23, lines 18-25).

Applicant submits that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicant's attorney/agent would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney/agent of record.

Date: June 4, 2004

Respectfully submitted,



Name: Kathleen M. Williams
Registration No.: 34,380
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100